1. Bilezikian JP, Khan AA, Potts JT Jr. Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab. 2009; 94:335–9.
2. Silverberg SJ, Clarke BL, Peacock M, Bandeira F, Boutroy S, Cusano NE, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014; 99:3580–94.
Article
3. Cusano NE, Silverberg SJ, Bilezikian JP. Normocalcemic primary hyperparathyroidism. J Clin Densitom. 2013; 16:33–9.
Article
4. Coe FL, Canterbury JM, Firpo JJ, Reiss E. Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria. J Clin Invest. 1973; 52:134–42.
Article
5. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011; 96:53–8.
Article
6. Fuleihan Gel-H, Bouillon R, Clarke B, Chakhtoura M, Cooper C, McClung M, et al. Serum 25-hydroxyvitamin D levels: variability, knowledge gaps, and the concept of a desirable range. J Bone Miner Res. 2015; 30:1119–33.
Article
7. Eastell R, Brandi ML, Costa AG, D’Amour P, Shoback DM, Thakker RV. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014; 99:3570–9.
Article
8. Giustina A, Adler RA, Binkley N, Bouillon R, Ebeling PR, Lazaretti-Castro M, et al. Controversies in vitamin D: summary statement from an international conference. J Clin Endocrinol Metab. 2019; 104:234–40.
Article
9. Madeo B, De Vincentis S, Repaci A, Altieri P, Vicennati V, Kara E, et al. The calcium-to-phosphorous (Ca/P) ratio in the diagnosis of primary hyperparathyroidism and hypoparathyroidism: a multicentric study. Endocrine. 2020; 68:679–87.
Article
10. Schini M, Jacques RM, Oakes E, Peel NFA, Walsh JS, Eastell R. Normocalcemic hyperparathyroidism: study of its prevalence and natural history. J Clin Endocrinol Metab. 2020; 105:e1171–86.
Article
11. Zaidan J, Wang X. Letter to the editor: “Normocalcemic hyperparathyroidism: study of its prevalence and natural history”. J Clin Endocrinol Metab. 2020; 105:dgaa275.
Article
12. Schini M, Eastell R. Response to letter to the editor: “Normocalcemic hyperparathyroidism: study of its prevalence and natural history”. J Clin Endocrinol Metab. 2020; 105:e2689.
Article
13. Schini M, Jacques R, Oakes E, Peel N, Walsh JS, Eastell R. Normocalcaemic hyperparathyroidism and primary hyperparathyroidism: least significant change for adjusted serum calcium. Eur J Endocrinol. 2021; 184:K7–10.
Article
14. Bland JM, Altman DG. Measurement error. BMJ. 1996; 313:744.
15. Cusano NE, Maalouf NM, Wang PY, Zhang C, Cremers SC, Haney EM, et al. Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J Clin Endocrinol Metab. 2013; 98:2734–41.
Article
16. Lundgren E, Rastad J, Thrufjell E, Akerstrom G, Ljunghall S. Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery. 1997; 121:287–94.
Article
17. Berger C, Almohareb O, Langsetmo L, Hanley DA, Kovacs CS, Josse RG, et al. Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers. Clin Endocrinol (Oxf). 2015; 82:359–68.
Article
18. Kontogeorgos G, Trimpou P, Laine CM, Olerod G, Lindahl A, Landin-Wilhelmsen K. Normocalcaemic, vitamin D-sufficient hyperparathyroidism: high prevalence and low morbidity in the general population. A long-term follow-up study, the WHO MONICA project, Gothenburg, Sweden. Clin Endocrinol (Oxf). 2015; 83:277–84.
19. Garcia-Martin A, Reyes-Garcia R, Munoz-Torres M. Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women. Endocrine. 2012; 42:764–6.
Article
20. Amaral LM, Queiroz DC, Marques TF, Mendes M, Bandeira F. Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone? J Osteoporos. 2012; 2012:128352.
Article
21. Maruani G, Hertig A, Paillard M, Houillier P. Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab. 2003; 88:4641–8.
Article
22. Tordjman KM, Greenman Y, Osher E, Shenkerman G, Stern N. Characterization of normocalcemic primary hyperparathyroidism. Am J Med. 2004; 117:861–3.
Article
23. Silverberg SJ, Bilezikian JP. “Incipient” primary hyperparathyroidism: a “forme fruste” of an old disease”. J Clin Endocrinol Metab. 2003; 88:5348–52.
Article
24. Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab. 2007; 92:3001–5.
Article
25. Wade TJ, Yen TW, Amin AL, Wang TS. Surgical management of normocalcemic primary hyperparathyroidism. World J Surg. 2012; 36:761–6.
Article
26. Koumakis E, Souberbielle JC, Sarfati E, Meunier M, Maury E, Gallimard E, et al. Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab. 2013; 98:3213–20.
Article
27. Marques TF, Vasconcelos R, Diniz E, Rego D, Griz L, Bandeira F. Normocalcemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat? Arq Bras Endocrinol Metabol. 2011; 55:314–7.
Article
28. Cakir I, Unluhizarci K, Tanriverdi F, Elbuken G, Karaca Z, Kelestimur F. Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism. Endocrine. 2012; 42:419–22.
Article
29. Siprova H, Frysak Z, Soucek M. Primary hyperparathyroidism, with a focus on management of the normocalcemic form: to treat or not to treat? Endocr Pract. 2016; 22:294–301.
Article
30. Palermo A, Naciu AM, Tabacco G, Falcone S, Santonati A, Maggi D, et al. Clinical, biochemical, and radiological profile of normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab. 2020; 105:dgaa174.
Article
31. Lemos ALP, Andrade SRL, Pontes LLH, Teixeira PMC, Bandeira E, Bandeira LC, et al. High rate of occult urolithiasis in normocalcemic primary hyperparathyroidism. Kidney Blood Press Res. 2019; 44:1189–95.
Article
32. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med. 1999; 341:1249–55.
Article
33. Cesareo R, Di Stasio E, Vescini F, Campagna G, Cianni R, Pasqualini V, et al. Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism. Osteoporos Int. 2015; 26:1295–302.
Article
34. Tang J, Mettler P, McFann K, Chonchol M. The association of prevalent kidney stone disease with mortality in US adults: the National Health and Nutrition Examination Survey III, 1988–1994. Am J Nephrol. 2013; 37:501–6.
Article
35. Brardi S, Cevenini G, Verdacchi T, Romano G, Ponchietti R. Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study. Arch Ital Urol Androl. 2015; 87:66–71.
Article
36. Saxena T, Ali AO, Saxena M. Pathophysiology of essential hypertension: an update. Expert Rev Cardiovasc Ther. 2018; 16:879–87.
Article
37. Rossi GP, Lenzini L. Vitamin D supplementation: a novel therapy for aldosteronism? Nat Rev Endocrinol. 2020; 16:303–4.
Article
38. Tomaschitz A, Ritz E, Pieske B, Rus-Machan J, Kienreich K, Verheyen N, et al. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. Metabolism. 2014; 63:20–31.
Article
39. Oinonen L, Tikkakoski A, Koskela J, Eraranta A, Kahonen M, Niemela O, et al. Parathyroid hormone may play a role in the pathophysiology of primary hypertension. Endocr Connect. 2021; 10:54–65.
Article
40. Kometani M, Yoneda T, Aono D, Gondoh-Noda Y, Matsuoka T, Higashitani T, et al. Primary aldosteronism with parathyroid hormone elevation: a single-center retrospective study. Intern Med. 2021; 60:993–8.
Article
41. Chen G, Xue Y, Zhang Q, Xue T, Yao J, Huang H, et al. Is normocalcemic primary hyperparathyroidism harmful or harmless? J Clin Endocrinol Metab. 2015; 100:2420–4.
Article
42. Beysel S, Caliskan M, Kizilgul M, Apaydin M, Kan S, Ozbek M, et al. Parathyroidectomy improves cardiovascular risk factors in normocalcemic and hypercalcemic primary hyperparathyroidism. BMC Cardiovasc Disord. 2019; 19:106.
Article
43. Mesquita PN, Dornelas Leao Leite AP, Chagas Crisostomo SD, Veras Filho E, da Cunha Xavier L, Bandeira F. Evaluation of coronary calcium score in patients with normocalcemic primary hyperparathyroidism. Vasc Health Risk Manag. 2017; 13:225–9.
Article
44. Pepe J, Colangelo L, Sonato C, Occhiuto M, Ferrara C, Del Fattore A, et al. Echocardiographic findings in patients with normocalcemic primary hyperparathyroidism compared with findings in hypercalcemic primary hyperparathyroid patients and control subjects. Endocr Pract. 2021; 27:21–6.
45. Bollerslev J, Sjostedt E, Rejnmark L. Cardiovascular consequences of parathyroid disorders in adults. Ann Endocrinol (Paris). 2021; 82:151–7.
Article
46. Karras SN, Koufakis T, Tsekmekidou X, Antonopoulou V, Zebekakis P, Kotsa K. Increased parathyroid hormone is associated with higher fasting glucose in individuals with normocalcemic primary hyperparathyroidism and prediabetes: a pilot study. Diabetes Res Clin Pract. 2020; 160:107985.
Article
47. Karras S, Annweiler C, Kiortsis D, Koutelidakis I, Kotsa K. Improving glucose homeostasis after parathyroidectomy for normocalcemic primary hyperparathyroidism with co-existing prediabetes. Nutrients. 2020; 12:3522.
Article
48. Pacifici R. Role of gut microbiota in the skeletal response to PTH. J Clin Endocrinol Metab. 2021; 106:636–45.
Article
49. Bannani S, Christou N, Guerin C, Hamy A, Sebag F, Mathonnet M, et al. Effect of parathyroidectomy on quality of life and non-specific symptoms in normocalcaemic primary hyperparathyroidism. Br J Surg. 2018; 105:223–9.
Article
50. Voss L, Nobrega M, Bandeira L, Griz L, Rocha-Filho PAS, Bandeira F. Impaired physical function and evaluation of quality of life in normocalcemic and hypercalcemic primary hyperparathyroidism. Bone. 2020; 141:115583.
Article
51. Pretorius M, Lundstam K, Hellstrom M, Fagerland MW, Godang K, Mollerup C, et al. Effects of parathyroidectomy on quality of life: 10 years of data from a prospective randomized controlled trial on primary hyperparathyroidism (the SIPH-Study). J Bone Miner Res. 2021; 36:3–11.
Article
52. Pandian TK, Lubitz CC, Bird SH, Kuo LE, Stephen AE. Normocalcemic hyperparathyroidism: a Collaborative Endocrine Surgery Quality Improvement Program analysis. Surgery. 2020; 167:168–72.
Article
53. Trinh G, Rettig E, Noureldine SI, Russell JO, Agrawal N, Mathur A, et al. Surgical management of normocalcemic primary hyperparathyroidism and the impact of intraoperative parathyroid hormone testing on outcome. Otolaryngol Head Neck Surg. 2018; 159:630–7.
Article
54. Graves CE, McManus CM, Chabot JA, Lee JA, Kuo JH. Biochemical profile affects IOPTH kinetics and cure rate in primary hyperparathyroidism. World J Surg. 2020; 44:488–95.
Article
55. Sho S, Kuo EJ, Chen AC, Li N, Yeh MW, Livhits MJ. Biochemical and skeletal outcomes of parathyroidectomy for normocalcemic (incipient) primary hyperparathyroidism. Ann Surg Oncol. 2019; 26:539–46.
Article
56. Traini E, Bellantone R, Tempera SE, Russo S, De Crea C, Lombardi CP, et al. Is parathyroidectomy safe and effective in patients with normocalcemic primary hyperparathyroidism? Langenbecks Arch Surg. 2018; 403:317–23.
Article